BACKGROUND: Most patients with multiple sclerosis without previous optic neuritis have thinner retinal layers than healthy controls. We assessed the role of peripapillary retinal nerve fibre layer (pRNFL) thickness and macular volume in eyes with no history of optic neuritis as a biomarker of disability worsening in a cohort of patients with multiple sclerosis who had at least one eye without optic neuritis available. METHODS: In this multicentre, cohort study, we collected data about patients (age ≥16 years old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive multiple sclerosis. Patients were recruited from centres in Spain, Italy, France, Germany, Czech Republic, Netherlands, Canada, and the USA, with the first cohort starting in 2008 and the latest cohort starting in 2013. We assessed disability worsening using the Expanded Disability Status Scale (EDSS). The pRNFL thickness and macular volume were assessed once at study entry (baseline) by optical coherence tomography (OCT) and was calculated as the mean value of both eyes without optic neuritis for patients without a history of optic neuritis or the value of the non-optic neuritis eye for patients with previous unilateral optic neuritis. Researchers who did the OCT at baseline were masked to EDSS results and the researchers assessing disability with EDSS were masked to OCT results. We estimated the association of pRNFL thickness or macular volume at baseline in eyes without optic neuritis with the risk of subsequent disability worsening by use of proportional hazards models that included OCT metrics and age, disease duration, disability, presence of previous unilateral optic neuritis, and use of disease-modifying therapies as covariates. FINDINGS: 879 patients with clinically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progressive multiple sclerosis (n=141) were included in the primary analyses. Disability worsening occurred in 252 (29%) of 879 patients with multiple sclerosis after a median follow-up of 2·0 years (range 0·5-5 years). Patients with a pRNFL of less than or equal to 87 μm or less than or equal to 88 μm (measured with Spectralis or Cirrus OCT devices) had double the risk of disability worsening at any time after the first and up to the third years of follow-up (hazard ratio 2·06, 95% CI 1·36-3·11; p=0·001), and the risk was increased by nearly four times after the third and up to the fifth years of follow-up (3·81, 1·63-8·91; p=0·002). We did not identify meaningful associations for macular volume. INTERPRETATION: Our results provide evidence of the usefulness of monitoring pRNFL thickness by OCT for prediction of the risk of disability worsening with time in patients with multiple sclerosis. FUNDING: Instituto de Salud Carlos III.

Charles University Prague Czech Republic

Cleveland Clinic Foundation Cleveland OH USA

Experimental and Clinical Research Center and NeuroCure Clinical Research Center Charité University Medicine and Max Delbrueck Center for Molecular Medicine Berlin Germany

Glostrup Hospital University of Copenhagen Denmark

Hospital Clinico San Carlos Madrid Spain

Hospital Miguel Servet Zaragoza Spain

Institut d'Investigacions Biomèdiques August Pi Sunyer Barcelona Spain

Institut d'Investigacions Biomèdiques August Pi Sunyer Barcelona Spain; University of California San Francisco CA USA

Johns Hopkins University Baltimore MD USA

San Raffaele Hospital Milan Italy

Save Sight Institute University of Sydney NSW Australia

University of Calgary Calgary AB Canada

University of California San Francisco CA USA

University of Düsseldorf Düsseldorf Germany

University of Lille Lille France

University of Pennsylvania Philadelphia PA USA

University of Pennsylvania Philadelphia PA USA; New York University New York NY USA

University of Texas Southwestern Medical Center Dallas TX USA

University of Zurich Zurich Switzerland

VU Medical Center Amsterdam Netherlands

VU Medical Center Amsterdam Netherlands; Moorfields Eye Hospital London UK

Komentář v

Lancet Neurol. 2016 May;15(6):537-8. doi: 10.1016/S1474-4422(16)00113-7. PubMed

Citace poskytuje Crossref.org

Assessing disease progression and treatment response in progressive multiple sclerosis

Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness z Scores

Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis

Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide

Do eyes with and without optic neuritis in multiple sclerosis age equally?

Current status of biomarker research in neurology